Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Arrowdhead Pharmaceuticals was founded by scientist Peter Emtage in 2002. The company started out as a small research firm working on a number of projects related to drug discovery and development. For the past several years, Arrowhead has been focused on its RNAi therapeutics technology, which involves using short interfering ribonucleic acid (siRNA) to “silence” unwanted disease-causing genes in the body.
The mission of Arrowhead Pharmaceuticals is to be a leader in the discovery and development of innovative therapeutics utilizing its proprietary technology platform to rapidly and cost-effectively advance new treatments to patients with serious diseases.
Arrowhead Pharmaceuticals vision is to be a leader in the discovery, development and commercialization of RNAi therapeutics, enabling improved life outcomes for people suffering from serious medical conditions.
Dr. James C. Hamilton M.D., MBA (Sr. VP of Discovery & Translational Medicine)
Dr. Javier San Martin M.D. (Chief Medical Officer)
Dr. Mark M. Davis Ph.D. (Founder and Founder & Director of Insert Therapeutics Inc & Calando)
Dr. Vincent Anzalone CFA (Head of Investor Relations & VP)
Mr. Howard Lovy (Director of Communications)
Dr. Mark Seefeld (Head of Toxicology & VP)
Ms. Tracie Oliver (Chief Commercial Officer)
Recognition and Awards
In 2018, Arrowhead Pharmaceuticals was recognized with an R&D 100 Award for its siRNA-based hepatitis B treatment. In 2020, Arrowhead was selected as one of the top ten “Hot Innovators” by CBInsights for its innovative approach to drug development.